| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA290: Mirabegron for treating symptoms of overactive bladder |
|
Medicine details |
|
| Medicine name | mirabegron (Betmiga®) |
| Formulation | 25 mg, 50 mg prolonged-release tablet |
| Reference number | 1169 |
| Indication | Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder syndrome |
| Company | Astellas Pharma Ltd |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 08/11/2012 |
| NICE guidance | TA290: Mirabegron for treating symptoms of overactive bladder |